Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • gurtecho
    Junior Member
    • Dec 2015
    • 4

    Bacterial RNA-seq Spike-in Controls

    Hello,

    I recently learned of RNA spike-in controls and am interested in incorporating them into my sequencing runs. I primarily use RNA-seq to measure gene expression levels in E. coli.

    My question is, are their RNA spike-in controls similar to those by the ERCC available for bacterial studies? If not, could you provide me with a suggestion on how to control for batch effects between sequencing runs?

    Thank you
  • blancha
    Senior Member
    • May 2013
    • 367

    #2
    I'm very skeptical on the value of ERCC spike-ins.
    I don't see the value of a control that cannot be fully trusted.

    More than one study has questioned the validity of ERCC spike-ins.



    My own, albeit limited, experience with spike-ins confirms the results of these studies.

    What is the point of the extra cost of adding the spike-ins, to end up with unreliable data requiring extra analysis?

    It's a nice concept, but I don't think the real-world results support the wide-spread use of the ERCC spike-ins.

    NGS is not like microarrays either. The batch effect is not as huge a problem between sequencing runs as it is for microarrays prepared at different times. Any batch effect, if present, would be more likely to result from manipulations prior to the sequencing itself.

    ---

    One way of controlling for any potential batch effect, albeit perhaps not cost-effective, would be to distribute the replicates across the sequencing runs. If you could verify that the replicates within the same sequencing run had the same correlation as replicates across sequencing runs, you could confidently discount any batch effect. Even if you did pick up a batch effect, in theory, it would be possible to correct it. I've used Combat, with some success in the past, to reduce the batch effect in microarray samples with replicates distributed thus between the different preparation times. Again, this may be too expensive for NGS, and less necessary, given the reduced batch effect.
    Last edited by blancha; 12-04-2015, 08:35 PM.

    Comment

    • Adiro
      Junior Member
      • Jan 2019
      • 4

      #3
      I'm wondering if anything changed...

      Anyone has an updated answer?

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
        by SEQadmin2


        Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

        The systematic characterization of the human proteome has
        ...
        07-20-2026, 11:48 AM
      • SEQadmin2
        Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
        by SEQadmin2



        Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
        ...
        07-09-2026, 11:10 AM
      • SEQadmin2
        Cancer Drug Resistance: The Lingering Barrier to Rising Survival
        by SEQadmin2



        Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

        There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
        07-08-2026, 05:17 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, 07-24-2026, 12:17 PM
      0 responses
      31 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-23-2026, 11:41 AM
      0 responses
      23 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-20-2026, 11:10 AM
      0 responses
      215 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-13-2026, 10:26 AM
      0 responses
      79 views
      0 reactions
      Last Post SEQadmin2  
      Working...